For instance, a logical extension of this work would be to test the efficacy of molecular targeting of RBNSig-associated drug targets such as Fanconi anemia nuclear complex or dual targeting of EHMT2/EZH2 (82) in preclinical models that harbor RBness. The gene discussed is EZH2; the disease is Fanconi anemia.